Close menu

December 9th, 2020 | 14:16 CET

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

  • Medical
Photo credits:

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

time to read: 2 minutes | Author: Nico Popp
ISIN: CA91915B1085 , NL0015436031 , US60770K1079 , DE0007165631

Table of contents:

    Valeo Pharma: drug for Covid-19 therapy receives approval

    "The regulatory approval of Redesca is a significant corporate milestone for Valeo and also great news for the Canadian healthcare system," commented Steve Saviuk, President and CEO of Valeo. Redesca is a heparin product. Such active ingredients have been tried and tested for many years and are traditionally used in the treatment of thrombosis.

    Recently, the World Health Organization (WHO) announced that Redesca could also be used in the treatment of Covid-19 to prevent further complications associated with infection. The market for such products in Canada is currently worth approximately CAD 200 million. Valeo Pharma expects to gain market share with its new product. "We expect Redesca to play a major role in the achievement of our growth objectives," Saviuk said in a Company release.

    Redesca, the newly approved drug, is a biosimilar, i.e. a generic version of a biopharmaceutical. Since this type of medication is usually cheaper than originals and healthcare systems are in a saving mode, biosimilars and generics are increasingly in demand. Valeo Pharma's shares have also been in demand recently: last month alone, the value increased by around 25%. The latest news increases the likelihood that the Company's ambitious growth targets will be achieved - this could also be a good sign for the share.

    CureVac: Fantasy knows no bounds

    The Tübingen vaccine pioneer, CureVac, is doing almost frighteningly well: in the past month alone, the paper has increased by a whopping 150%. In the opinion of many traders and market experts, such a development calls for a correction. But CureVac has developed a vaccine against the coronavirus and is also a leader in mRNA technology, which enables the human body to produce its own medicine.

    Beyond the pandemic, the market for CureVac shares is already spinning further and further: Will there soon be a vaccination against cancer? Will diseases of civilization or Alzheimer be defeated soon? Given the development of vaccines in record time, it seems that there are currently no limits for biotech stocks. However, investors should be cautious and limit their risk given the stocks rapid gains. At the moment, it is advisable not to invest in the stock.

    Moderna: Money shower ahead?

    The situation is similar with Moderna. The shares of the US biotech Company are also benefiting from the effective vaccine presented a few weeks ago. Like CureVac, Moderna is also focusing on mRNA technology in the hope of being able to treat other diseases or produce a vaccine against them in the future. Given the promising clinical results and the high efficacy of the vaccines of Moderna and CureVac, both Companies could be in for a real windfall.

    Cautious investors pay attention to the drop in price

    If the biotech pioneers invest these funds in the development of new products, the growth of Moderna and CureVac could increase. But despite this fantasy, investors should not think too far into the future at current valuation levels. As with CureVac, Moderna is currently subject to greater risk for investors. Companies such as the Canadian Valeo Pharma or Sartorius, the Goettingen-based supplier of laboratory equipment, may not exude as much fantasy, but they have a lower fall.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Mario Hose on May 5th, 2020 | 08:33 CEST

    Evotec, Medigene, Memphasys - the right investment timing

    • Medical

    The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.


    Commented by Mario Hose on April 24th, 2020 | 07:36 CEST

    BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

    • Medical

    There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.


    Commented by Mario Hose on March 4th, 2020 | 07:27 CET

    Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

    • Medical

    In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.